Geode Capital Management LLC increased its stake in shares of Alkermes Plc (NASDAQ:ALKS) by 1.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,333,429 shares of the company’s stock after acquiring an additional 21,608 shares during the period. Geode Capital Management LLC owned about 0.87% of Alkermes worth $72,934,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. First Trust Advisors LP raised its holdings in Alkermes by 18.6% during the fourth quarter. First Trust Advisors LP now owns 800,752 shares of the company’s stock worth $43,825,000 after acquiring an additional 125,309 shares in the last quarter. Bailard Inc. bought a new stake in Alkermes during the fourth quarter worth about $274,000. Schwab Charles Investment Management Inc. raised its holdings in Alkermes by 5.0% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 493,515 shares of the company’s stock worth $27,011,000 after acquiring an additional 23,712 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Alkermes by 13.7% during the third quarter. Janus Henderson Group PLC now owns 2,650,006 shares of the company’s stock worth $134,726,000 after acquiring an additional 319,014 shares in the last quarter. Finally, AMP Capital Investors Ltd raised its holdings in Alkermes by 11.0% during the third quarter. AMP Capital Investors Ltd now owns 53,745 shares of the company’s stock worth $2,732,000 after acquiring an additional 5,306 shares in the last quarter.
In other news, insider Shane Cooke sold 72,793 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $60.55, for a total value of $4,407,616.15. Following the transaction, the insider now owns 147,501 shares of the company’s stock, valued at $8,931,185.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Laurie Keating sold 6,249 shares of the company’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total value of $757,378.80. The disclosure for this sale can be found here. Insiders sold 125,433 shares of company stock worth $7,942,327 in the last 90 days. Corporate insiders own 5.34% of the company’s stock.
Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Wednesday, February 14th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.32. The firm had revenue of $275.37 million for the quarter, compared to analyst estimates of $251.23 million. Alkermes had a negative return on equity of 4.32% and a negative net margin of 17.48%. The business’s revenue for the quarter was up 29.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.02 earnings per share. equities research analysts forecast that Alkermes Plc will post -0.8 EPS for the current fiscal year.
Several research firms recently issued reports on ALKS. Morgan Stanley reiterated an “equal weight” rating and set a $67.00 target price (up previously from $60.00) on shares of Alkermes in a report on Friday, February 23rd. BidaskClub upgraded Alkermes from a “sell” rating to a “hold” rating in a report on Friday, January 26th. Credit Suisse Group upped their target price on Alkermes from $66.00 to $70.00 and gave the stock an “outperform” rating in a report on Friday, February 16th. Citigroup set a $62.00 target price on Alkermes and gave the stock a “hold” rating in a report on Thursday, February 15th. Finally, Zacks Investment Research upgraded Alkermes from a “hold” rating to a “buy” rating and set a $71.00 target price on the stock in a report on Monday, February 5th. Nine equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Alkermes presently has a consensus rating of “Hold” and a consensus price target of $64.58.
Alkermes Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.